Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo.
Immunity. 2000 Jun;12(6):643-52. Unique Identifier : AIDSLINE MED/20350662 Agarwal S; Avni O; Rao A; Department of Pathology, Harvard Medical School and the Center; for Blood Research, Boston, Massachusetts 02115, USA.
Abstract:
By DNase I hypersensitivity analysis, we have identified an inducible, cyclosporin A-sensitive enhancer located 3' of the interleukin-4 (IL-4) gene. The enhancer binds the Th2-specific transcription factor GATA3 in vivo but is not perceptibly influenced by the absence of a second Th2-specific factor, cMaf. The antigen-inducible transcription factor NFAT1 binds the IL-4 enhancer and the IL-4 promoter only in stimulated Th2 cells; conversely, NFAT1 binds to the interferon (IFN)-gamma promoter only in stimulated Th1 cells. Our results support a model whereby transcription factors such as NFAT1, which are nonselectively induced in antigen-stimulated T cells, gain access to cytokine regulatory regions only in the appropriate subset of differentiated T cells in vivo. This restricted access enables antigen-dependent and subset-specific transcription of cytokine genes.
Keywords: JOURNAL ARTICLE Animal Base Sequence Binding Sites/DRUG EFFECTS/GENETICS/IMMUNOLOGY Clone Cells Cyclosporine/PHARMACOLOGY Cytokines/GENETICS Deoxyribonuclease I/METABOLISM DNA-Binding Proteins/*METABOLISM/PHYSIOLOGY Enhancer Elements (Genetics)/DRUG EFFECTS/*IMMUNOLOGY Gene Expression Regulation/DRUG EFFECTS/IMMUNOLOGY Interleukin-4/GENETICS/*METABOLISM Mice Mice, Inbred C57BL Molecular Sequence Data Proto-Oncogene Proteins/PHYSIOLOGY Regulatory Sequences, Nucleic Acid/DRUG EFFECTS/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Th2 Cells/DRUG EFFECTS/METABOLISM Trans-Activators/METABOLISM Transcription Factors/*METABOLISM 3' Untranslated Regions/DRUG EFFECTS/METABOLISM 001030
A00A1126
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
